biostudies-literatureDilley JCancer Research UKBarts CharityMedical Research CouncilNational Institute for Health Research (NIHR)123-130https://www.ebi.ac.uk/biostudies/studies/S-EPMC7616840biostudies-literatureUnknown179<h4>Objective</h4>UKCTOCS provides an opportunity to explore symptoms in preclinical invasive epithelial ovarian cancer (iEOC). We report on symptoms in women with pre-clinical (screen-detected) cancers (PC) compared to clinically diagnosed (CD) cancers.<h4>Methods</h4>In UKCTOCS, 202638 postmenopausal women, aged 50-74 were randomly allocated (April 17, 2001-September 29, 2005) 2:1:1 to no screening or annual screening till Dec 31,2011, using a multimodal or ultrasound strategy. Follow-up was through national registries. An outcomes committee adjudicated on OC diagnosis, histotype, stage. Eligible women were those diagnosed with iEOC at primary censorship (Dec 31, 2014). Symptom details were extracted from trial clinical-assessment forms and medical records. Descriptive statistics were usGynecologic oncologyOvarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).PMC7616840G0801228CL-2009-18-006MGU046116/46/01MR_UU_12023MC_UU_12023/28MC_UU_00004/01C1479/A2884G9901012Dilley JBurnell MCampbell SJacobs IRyan AMcGuire AMenon USharma AMould TKalsi JSingh NGentry-Maharaj AWoolas RParmar MWilliamson KSkates SJManchanda RFallowfield LfalseOvarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).<h4>Objective</h4>UKCTOCS provides an opportunity to explore symptoms in preclinical invasive epithelial ovarian cancer (iEOC). We report on symptoms in women with pre-clinical (screen-detected) cancers (PC) compared to clinically diagnosed (CD) cancers.<h4>Methods</h4>In UKCTOCS, 202638 postmenopausal women, aged 50-74 were randomly allocated (April 17, 2001-September 29, 2005) 2:1:1 to no screening or annual screening till Dec 31,2011, using a multimodal or ultrasound strategy. Follow-up was through national registries. An outcomes committee adjudicated on OC diagnosis, histotype, stage. Eligible women were those diagnosed with iEOC at primary censorship (Dec 31, 2014). Symptom details were extracted from trial clinical-assessment forms and medical records. Descriptive statistics were us2023-01-01T00:00:00Z2023 Dec2026-04-08T19:13:06.954Z2025-04-04T22:47:12.956ZS-EPMC76168403798076710.1016/j.ygyno.2023.11.005